Cerenis Therapeutics, Inc.

42 articles with Cerenis Therapeutics, Inc.

• Cerenis Therapeutics announces its cash position for Q3 2018 and highlights the progress made over the period and key perspectives for the end of 2018

  10/25/2018

  Progress in Q3 2018

• CERENIS to Present New Data Validating HDL Targeted Drug Delivery in the Field of Oncology and Immuno-Oncology at the 30th EORTC/NCI/AACR1 Symposium

  10/22/2018

  Cerenis Therapeutics (FR0012616852 – CEREN – PEA-PME eligible) (Paris:CEREN), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases,

• 

  Biotech Movers and Shakers for Aug. 6

  8/6/2018

  Biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those adjustments.

• Cerenis Announces Today the Appointment of Barbara Yanni to Its Board of Directors as an Independent Director

  7/31/2018

  Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular, metabolic diseases, and new HDL-based vectors for the targeted drug delivery in the oncology field announces today the appointment of Barbara Yanni to its Board of Directors as an Independent Director.

• Cerenis Announces Financing from Investment Funds, Management, Its Board of Directors and Its Oncology Scientific Advisory Board

  7/26/2018

  Cerenis Therapeutics announces a capital increase of more than one million euros for the financing of its immuno-oncology activities.

• CERENIS Therapeutics and University of North Texas Health Science Center Announce a Strategic Initiative to Develop New HDL-Based Pharmaceutical Products

  5/29/2018

  This joint program is another marker of Cerenis' strategic evolution into a company with novel HDL platforms for drug delivery.

• Seasoned Scientific Experts and Strategic Pharmaceutical Industry Veterans Join Cerenis’ Scientific Advisory Board in Oncology

  5/2/2018

  CERENIS Therapeutics announces the creation of its Scientific Advisory Board in Oncology (SAB-Oncology) with five key appointments.

• First Patients Enter TARGET Study, Recently Initiated by Cerenis Therapeutics to Evaluate HDL Nanoparticles in Patients with Esophageal Cancer

  11/22/2017

  TARGET is the first ever performed clinical study testing the potential of labelled HDL to visualize tumors in cancer patients.

• CERENIS Therapeutics Acquires LYPRO Biosciences Expanding Its HDL Strategy Into Immuno-Oncology and Chemotherapeutic Drug Delivery

  11/8/2017

  Financial terms of the LYPRO Biosciences assets acquisition by CERENIS Therapeutics are not disclosed.

• Cerenis Therapeutics, Inc. Receives FDA IND Approval To Begin Studies With CER-209 In NAFLD And NASH

  12/16/2016

• Cerenis Therapeutics, Inc. Announces Last Patient Dosed In CARAT Phase II Study With CER-001 In Post-Acute Coronary Syndrome Patients

  11/8/2016

• Cerenis Therapeutics, Inc. Release: Publication Of The Location Clinical Study Results In The Renowned Scientific Journal Of The European Atherosclerosis Society

  6/2/2016

• Cerenis Therapeutics, Inc. Featured Prominently At The 25th Conference Of The Asian Pacific Association For The Study Of The Liver (APASL)

  2/25/2016

• Catalent Biologics And Cerenis Therapeutics, Inc. Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology

  1/28/2016

• Cerenis Therapeutics, Inc.: New Data For CER-001 Presented In Key Oral Session At American Heart Association Conference 2015

  11/10/2015

• Cerenis Therapeutics, Inc. Announces The Results Of The LOCATION Study

  7/15/2015

• Cerenis Therapeutics, Inc. Announces The Appointment Of A New Chief Medical Officer And New Board Members

  2/9/2015

• Cerenis Therapeutics, Inc. Receives European Medicines Agency Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies

  9/3/2014

• Cerenis Therapeutics, Inc. Appoints Dr. Richard C. Pasternak As Chairman

  9/3/2014

• Cerenis Therapeutics, Inc. Reports Two Positive Phase II Studies For HDL Mimetic CER-001 At EAS

  6/2/2014